Mild cognitive impairment is associated with effect of uremic metabolites on gray matter structural changes in end-stage kidney disease.

ABSTRACT: To investigate the grey matter volume (GMV) changes and uremic metabolites in end-stage kidney disease (ESKD) patients with mild cognitive impairment (MCI) (ESKD-MCI) and further examine the classification and diagnostic efficacy of these features for ESKD-MCI patients. A total of 65 patients with ESKD, including 34 ESKD-MCI and 31 with non-cognitive impairment (ESKD-NCI), and 55 health controls (HCs) were enrolled. All participants underwent brain structural magnetic resonance imaging (MRI) scanning and Montreal cognitive assessment test. Clinical characteristics and GMV differences among these three groups were analyzed. In addition, mediation analysis was performed to determine the mediating effect of GMV changes on the association between clinical risk factors and MCI. Finally, support

SUBMITTER: Yuan H 

PROVIDER: S-EPMC12310915 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature